Stay updated on Pembrolizumab with Radiation in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with Radiation in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab with Radiation in Hodgkin Lymphoma Clinical Trial page
- Check4 days agoChange DetectedThe page now includes posted results with metrics such as Complete Response rate, Overall Response Rate, and 2-year Progression-Free Survival, along with the posting dates and a PDF of the Study Protocol and Statistical Analysis Plan. Older results-submission entries, including the complete response rate, have been removed.SummaryDifference2%

- Check11 days agoChange DetectedThe page shows a new revision label, updating from v3.6.5 to v3.6.6, indicating a minor update to the page version.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check33 days agoChange DetectedPage revision was updated from v3.6.4 to v3.6.5, signaling a software release or maintenance update to the ClinicalTrials.gov page. The update does not modify study details, eligibility criteria, or other content visible on the page.SummaryDifference0.1%

- Check47 days agoChange DetectedResults have been submitted for this study record, replacing the previous 'No Results Posted' status. The page revision has been updated from v3.6.3 to v3.6.4.SummaryDifference0.1%

- Check62 days agoChange DetectedMilestone dates for the study were updated to reflect revised timelines, including the primary completion date and the estimated study completion. The date of the most recent update was added.SummaryDifference0.3%

- Check69 days agoChange DetectedRevision tag updated from v3.6.2 to v3.6.3. This indicates a minor CMS update that does not modify study details or other substantive content on the page.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab with Radiation in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Radiation in Hodgkin Lymphoma Clinical Trial page.